Directorate Change

24 December 2014

Immunodiagnostic Systems Holdings plc

Directorate Change

Further to the announcement issued on 24 November 2014 that Patrik Dahlen, Chief Executive Officer, had given 12 months' notice to leave the Company, the Company announces that it has reached agreement with Patrik Dahlen for him to leave the Board and the Group with effect from 4 January 2015. The Company is undertaking a process to identify a new CEO. Until that appointment takes effect, Burkhard Wittek, the Company's Non-Executive Chairman, will become Executive Chairman (with effect from 4 January 2015). Upon the appointment of a new CEO, Burkhard Wittek will revert to being Non-Executive Chairman.

For further information:

About Immunodiagnostic Systems Holdings PLC

The Group's vision is to be a leading solution provider to the clinical laboratory diagnostic market. IDS's strategy is focused on developing, internally and through partnership, its automated assay menu for its proprietary automated immunoassay analyser, the IDS-iSYS system. Internally the Group is focused on developing an endocrinology excellence menu and externally IDS works with partners to develop assay panels in complementary indication fields. The Group sells its products primarily in the clinical laboratory market across a range of customers from reference laboratories to physician office laboratories. IDS has field sales forces in certain European countries, including France and Germany, the United States and Brazil and works with distributors in other markets including China, Italy and Spain.